Lab of Cognitive Neuroscience, School of Psychology, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Neuropsychiatr. 2021 Jun;35(2):92-97. doi: 10.1007/s40211-020-00345-x. Epub 2020 Apr 9.
Chemotherapeutic drugs often contribute to the cognitive impairment observed in some individuals following chemotherapy treatment. Postchemotherapy cognitive impairment (PCCI) is referred to as a decline in a variety of neuropsychological measures after chemotherapy and has an acute onset.
The goals of the present study are to compare the manifestation of longitudinal PCCI among 182 patients with four different types of cancer (breast, colorectal, prostate and thyroid cancer) before chemotherapy (T1), immediately after chemotherapy (T2) and 6 months later (T3).
Although no statistically significant differences were observed between the study groups in any of the cognitive domains before chemotherapy, patients with breast cancer showed significantly lower performance on all cognitive domains compared to other patients at the postchemotherapy timepoints.
Although cognitive difficulties are reported during and after chemotherapy for cancer, it seems that there are differences between different types of cancer. We conclude that it is particularly important to assess and manage these cognitive disorders. Management includes rehabilitation programs that can improve cognitive functions and contribute to changes in brain functions to facilitate this improvement.
化疗药物常常导致一些接受化疗治疗的个体出现认知障碍。化疗后认知障碍（PCCI）是指化疗后多种神经心理学测量值下降，且发病急。
本研究旨在比较 182 例患有四种不同类型癌症（乳腺癌、结直肠癌、前列腺癌和甲状腺癌）患者在化疗前（T1）、化疗后即刻（T2）和 6 个月后（T3）的纵向 PCCI 表现。
尽管在化疗前的任何认知领域，各组之间均无统计学差异，但乳腺癌患者在化疗后的所有认知领域的表现均明显低于其他患者。
尽管癌症化疗期间和之后均有报道称存在认知困难，但不同类型的癌症之间似乎存在差异。我们得出的结论是，评估和管理这些认知障碍尤为重要。管理包括康复计划，可改善认知功能并促进大脑功能的改变，从而促进这种改善。
